Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Cabaletta Bio ( (CABA) ) is now available.
Cabaletta Bio showcased promising clinical data on their CABA-201 treatment, which suggests potential drug-free responses in autoimmune diseases like myositis, systemic lupus erythematosus, and systemic sclerosis. The treatment demonstrated a favorable safety profile with no high-grade cytokine release syndrome observed. Moreover, the trials indicated consistent B cell depletion and early repopulation, hinting at an immune system reset. These findings were highlighted at the ACR Convergence 2024, sparking optimism for advancements in targeted cell therapies for autoimmune conditions.
Learn more about CABA stock on TipRanks’ Stock Analysis page.